Latest Insulin pen Stories

- Apidra(R) SoloSTAR(R) is a Convenient Insulin Delivery Device to Help Patients with Diabetes Improve Glycemic Control BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R) (insulin glulisine [rDNA origin] injection), a prefilled disposable pen containing rapid-acting insulin analog Apidra(R), which is indicated to improve glycemic control in adults and children (4 years and...

Eli Lilly and Company has introduced a color differentiation system for U-100 insulin products marketed in the US, including vials, pens and individual packaging for Humalog and Humulin. The Lilly color differentiation system - also used for Humalog and Humulin formulations marketed in Europe - follows the introduction of bar coding of packaging and insulin vials instituted in the US by Lilly in 2004. Combined, these safety measures offer patients, physicians, pharmacists and other...

BRIDGEWATER, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (4 years and older) with diabetes mellitus. The approval of Apidra(R) for pediatric use is based upon FDA review of a 26-week, phase III, open-label, active control study of Apidra(R) in comparison with insulin lispro, in 572 children and adolescents (4 years...

INDIANAPOLIS, Jan. 11 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced several strategic changes to its global manufacturing operations to better support the company's current product portfolio and evolving drug pipeline. "Lilly is continuing to transform its operations to compete and win in a more challenging business environment," said Scott Canute, Lilly's president of manufacturing operations. "As a part of these efforts, Lilly is making several changes to its global...